Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The clinical trial aims to study the safety and efficacy of transfusion of COVID-19 convalescent hyperimmune plasma for the treatment of moderate and severe forms of COVID-19 disease in comparison with non-convalescent fresh frozen plasma (standard plasma).
Description: The number and proportion of patients with the normal body temperature (≤37.2 C) at the days 1, 2, 3, 4, 5, 6, 7 after the start of therapy, for the statistical data comparison between the two arms.
Measure: The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy Time: Days 1, 2, 3, 4, 5, 6, 7Description: For each patient, the number of days passed from the plasma administration to placing on mechanical ventilation will be noted, for the statistical data comparison between the two arms.
Measure: Days before mechanical ventilation Time: 30 daysDescription: For each patient, the number of days he or she spent on the oxygen support after the plasma administration will be noted, for the statistical data comparison between the two arms.
Measure: Days of need for oxygen therapy Time: 30 daysDescription: For each patient, the entire duration of ICU stay after the plasma administration will be noted, for the statistical data comparison between the two arms.
Measure: Days of stay in the ICU Time: 30 daysDescription: For each patient, the entire duration of hospital stay after the plasma administration will be noted, for the statistical data comparison between the two arms.
Measure: Days of hospitalization Time: 30 daysDescription: Changes of the plasma levels of the SARS-CoV-2 antibodies, days 14 and 30 after the treatment start vs those levels before the treatment start (day 0) for the same patients.
Measure: Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients Time: Days 0, 14, 30Description: Changes of the plasma levels of IL2, IL6, IL10, TNFalpha and INFgamma, days 3 and 7 after the treatment start vs those levels before the treatment start (day 0) for the same patients.
Measure: Dynamics of the cytokine profile Time: Days 0, 3, 7Description: Incidence of administering IL6 receptor blockers (tocilizumab, sarilumab)
Measure: Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors Time: Days 3, 7Description: Changes of the plasma levels of C-reactive protein, days 1, 2, 3, 4, 5, 6, 7 after the treatment start vs those levels before the treatment start (Day 0) for the same patients.
Measure: Dynamics of the level of C-reactive protein Time: Days 0, 1, 2, 3, 4, 5, 6, 7Description: 30-day mortality rate, for the statistical data comparison between the two arms.
Measure: 30-day mortality rate Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports